A panelist discusses how to sequence the four approved cGVHD agents based on patient-specific factors, recommending exotilimab or belumosidil for lung involvement, any of the three oral agents for ...

Panelists discuss how JAK inhibitor therapy can benefit patients with intermediate-1–risk myelofibrosis despite being studied primarily in higher-risk patients in the COMFORT and JUMP trials.

Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, showed clinical benefit in patients with polycythemia vera in a phase 2 study, and 10 mg twice daily was established as an effective starting ...

Ruxolitinib improves hematocrit control and treatment response in polycythemia vera compared to best available therapy. Patients on ruxolitinib show better Myeloproliferative Neoplasms-Symptom ...

February 29, 2012 — The first drug ever approved for myelofibrosis, ruxolitinib (Jakafi, Incyte/Novartis), has shown results that are "unprecedented" in the treatment of this disorder ...

Both adolescents and adults saw improvements with the use of ruxolitinib or povorcitinib to treat their nonsegmental vitiligo. Nonsegmental vitiligo could be effectively treated by using either ...

Ruxolitinib cream (Opzelura, Incyte Dermatology), a Janus kinase (JAK) inhibitor, has shown efficacy and safety among adolescents and adults with AD. Only four of the 71 patients in the study ...

A recent study shows a medicated cream called ruxolitinib is extremely effective in about one-third of patients. The cream is giving patients hope that even if they don't benefit from the ...

Reduction in spleen volume of ≥35% from baseline at week 24 was met in 65.9 and 35.2% of patients randomly assigned to pelabresib-ruxolitinib and placebo-ruxolitinib, respectively. HealthDay ...

THURSDAY, March 27, 2025 (HealthDay News) -- Pelabresib, a bromodomain and extraterminal domain inhibitor, plus ruxolitinib (a Janus kinase [JAK] inhibitor) improves signs of underlying ...